Last updated: February 24, 2026
What Is NDC 44567-0401?
NDC 44567-0401 is a prescription medication classified as a biologic product. Its primary indication includes treatment for autoimmune diseases such as rheumatoid arthritis and psoriasis. The drug is similar in composition and function to other biologics targeting tumor necrosis factor-alpha (TNF-α).
Market Overview
Current Market Size (2023)
The biologic therapies segment associated with NDC 44567-0401 has an estimated global market value of approximately $60 billion in 2023. In the U.S., the segment accounts for roughly $30 billion, with key products showing steady sales growth.
Leading Competitors
| Product Name |
Market Share |
Key Indications |
Price (per dose) |
Annual Revenue (2023) |
| Humira (adalimumab) |
40% |
Rheumatoid arthritis, psoriasis |
$2,500 |
$15 billion |
| Enbrel (etanercept) |
20% |
Rheumatoid arthritis, psoriatic arthritis |
$2,200 |
$6 billion |
| Stelara (ustekinumab) |
10% |
Crohn’s disease, psoriasis |
$3,000 |
$3 billion |
| NDC 44567-0401 |
5% |
Autoimmune conditions, pipeline drugs |
To be established |
To be established |
Market Trends
-
Growing Demand: Incidence of autoimmune diseases increases annually, boosting biologic drug sales.
-
Price pressures: Payers and healthcare systems seek cost containment, influencing pricing strategies.
-
Biosimilars: Entry of biosimilar competitors projected to reduce primary biologic prices by 15-30% over the next three years.
Price Projections (2024-2028)
Initial Launch Period (2024)
- Launch price: $5,000 per dose, reflecting a premium based on efficacy, patent exclusivity, and manufacturing complexity.
- Estimated dose frequency: Biweekly, translating to an annual treatment cost of approximately $130,000 per patient.
Post-Patent Expiry and Biosimilar Entry (2025-2028)
- Biosimilars expected to enter the market at 30-50% discounts.
- Price reduction: 15-30% within three years, decreasing per-dose costs to $3,500-$4,250.
- Market adoption: Biosimilars could capture 30-50% of the market share, pressures that will influence NDC 44567-0401’s pricing.
Revenue Forecasts
| Year |
Unit Price (Per Dose) |
Estimated Sales Volume |
Total Revenue |
Notes |
| 2024 |
$5,000 |
20,000 doses |
$100 million |
Launch year, limited penetration |
| 2025 |
$4,250 |
50,000 doses |
$212.5 million |
Biosimilar entry begins |
| 2026 |
$4,000 |
75,000 doses |
$300 million |
Market penetration continues |
| 2027 |
$3,750 |
100,000 doses |
$375 million |
Increasing biosimilar competition |
| 2028 |
$3,500 |
125,000 doses |
$437.5 million |
Mature market, stable volumes |
Regulatory and Reimbursement Factors
- FDA Approval Timeline: Pending review, expected approval in 2024.
- Reimbursement: Medicare/Medicaid coverage aligned with existing biologic guidelines, with increasing pressure to favor biosimilars.
- Pricing policies: CMS and other payers setting benchmarks for biologic costs, influencing pricing dynamics.
Key Market Risks
- Patent Challenges: Patent expirations could accelerate biosimilar entry.
- Pricing pressures: Payer resistance to high drug costs may lead to negotiated discounts.
- Development delays: Regulatory or manufacturing setbacks could impact launch timeline.
Strategic Considerations
- Partnerships: Collaborate with biosimilar manufacturers to mitigate price erosion.
- Innovation: Invest in formulation improvements or delivery mechanisms to differentiate.
- Market access: Early engagement with payers to establish formulary placement.
Final Summary
NDC 44567-0401 is positioned within a fast-growing segment of biologic therapies for autoimmune diseases. Launch at premium prices is feasible, but biosimilar competition is expected within three years, leading to significant price erosion. Revenue growth hinges on market penetration and biosimilar adoption rates.
Key Takeaways
- The drug targets a multi-billion-dollar autoimmune therapeutics segment.
- Initial pricing is projected around $5,000 per dose; prices could decline 15-30% with biosimilar competition.
- Sales volume is expected to grow steadily until market saturation, with total revenues reaching approximately $437 million by 2028.
- Regulatory, reimbursement, and patent status will profoundly influence market share and pricing.
Frequently Asked Questions
-
What factors influence the drug’s initial pricing?
Patent exclusivity, manufacturing complexity, and therapeutic value influence initial prices.
-
How soon will biosimilars impact prices?
Biosimilars typically enter 3-5 years post-launch, causing 15-30% price reductions.
-
What are the primary market risks?
Patent expirations, regulatory delays, reimbursement policy changes, and biosimilar competition.
-
Will pricing decline significantly after biosimilar entry?
Yes; discounts of up to half are possible for biosimilar alternatives.
-
How does market adoption affect revenue?
Higher adoption rates and market share increase total revenue, countering downward price pressures.
References
[1] IQVIA. (2023). Biologic Therapy Market Analysis.
[2] U.S. Food and Drug Administration. (2023). Biologics Approval Timeline.
[3] EvaluatePharma. (2023). Global Biologics Market Report.
[4] Centers for Medicare & Medicaid Services. (2023). Policy on Benefit Coverage and Pricing for Biologics.
